Literature DB >> 30692861

What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale.

Bilge Piri Çinar1, Yüksel Güven Yorgun2.   

Abstract

Multiple Sclerosis (MS) is often seen in young adults and known to cause both physical and cognitive disability, and it is quite important to make an objective assessment of the physical-cognitive disability status of the patients. The first scale that assesses the physical disability in MS cases, the Disability Status Scale (DSS) elaborated in 1983 and transformed into the Expanded DSS (EDSS). It has been in use since 1983 without much change, which is one of its most significant advantages. It includes all functional systems (although with some shortcomings) that may be affected in MS and reflects the clinical status as a number, which is quite valuable. Although there may be differences between EDSS practitioners, it has been in use for more than 30 years and it can objectively display the difference between a patient's clinical picture 20 years ago and today, which can be said for only a small number of scales. This shows the importance of using the same scale for diseases that require long-term monitoring such as MS. In conclusion; it is a consensus that EDSS will not undergo major changes so that its greatest advantage can be preserved. Also, the consensus in the available literature is that EDSS will never lose its value.

Entities:  

Keywords:  Expanded disability status scale; multiple sclerosis; physical disability; progression

Year:  2018        PMID: 30692861      PMCID: PMC6278618          DOI: 10.29399/npa.23343

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  35 in total

1.  A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.

Authors:  M P Amato; G Ponziani; M L Bartolozzi; G Siracusa
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

Review 2.  Quantification of impairment in MS: discussion of the scales in use.

Authors:  M P Amato; G Ponziani
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

3.  A new scale for evaluating disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1955-08       Impact factor: 9.910

4.  The effects of isoniazid on patients with multiple sclerosis; preliminary report.

Authors:  J F KURTZKE; L BERLIN
Journal:  Am Rev Tuberc       Date:  1954-10

5.  Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test.

Authors:  J Bowen; L Gibbons; A Gianas; G H Kraft
Journal:  Mult Scler       Date:  2001-06       Impact factor: 6.312

6.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

7.  Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter.

Authors:  H Albrecht; C Wötzel; L P Erasmus; M Kleinpeter; N König; W Pöllmann
Journal:  Mult Scler       Date:  2001-04       Impact factor: 6.312

8.  The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity.

Authors:  Philippe Rossier; Derick T Wade
Journal:  Clin Rehabil       Date:  2002-02       Impact factor: 3.477

Review 9.  Minimal neuropsychological assessment of MS patients: a consensus approach.

Authors:  Ralph H B Benedict; Jill S Fischer; Cate J Archibald; Peter A Arnett; William W Beatty; Julie Bobholz; Gordon J Chelune; John D Fisk; Dawn W Langdon; Lauren Caruso; Fred Foley; Nicholas G LaRocca; Lindsey Vowels; Amy Weinstein; John DeLuca; Stephen M Rao; Frederick Munschauer
Journal:  Clin Neuropsychol       Date:  2002-08       Impact factor: 3.535

10.  Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  14 in total

1.  Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis.

Authors:  Patrícia Rodrigues; Guilherme Vargas Bochi; Gabriela Trevisan
Journal:  Mol Neurobiol       Date:  2021-08-15       Impact factor: 5.590

2.  Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.

Authors:  Bianca Weinstock-Guttman; Maria Pia Sormani; Pavle Repovic
Journal:  Int J MS Care       Date:  2022-10-05

Review 3.  Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis.

Authors:  Diulle Spat Peres; Patrícia Rodrigues; Fernanda Tibolla Viero; Julia Maria Frare; Sabrina Qader Kudsi; Graziela Moro Meira; Gabriela Trevisan
Journal:  Brain Behav Immun Health       Date:  2022-07-06

Review 4.  Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.

Authors:  Fernando Dangond; Alexis Donnelly; Reinhard Hohlfeld; Catherine Lubetzki; Susan Kohlhaas; Letizia Leocani; Olga Ciccarelli; Bruno Stankoff; Maria Pia Sormani; Jeremy Chataway; Federico Bozzoli; Francesco Cucca; Lisa Melton; Timothy Coetzee; Marco Salvetti
Journal:  Nat Rev Neurol       Date:  2021-01-22       Impact factor: 42.937

5.  A cross-sectional study of alexithymia in patients with relapse remitting form of multiple sclerosis.

Authors:  J Stojanov; A Stojanov
Journal:  J Postgrad Med       Date:  2020 Jan-Mar       Impact factor: 1.476

6.  [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis].

Authors:  Burkhard Domurath; Peter Flachenecker; Thomas Henze; Wolfgang Feneberg; Anna Brandt; Ines Kurze; Ruth Kirschner-Hermanns; Albert Kaufmann; Jörn Bremer; Manuela Vonthien; Kerstin Ratering; Christoph Schäfer; Will Nelson Vance; Paul Schmidt
Journal:  Nervenarzt       Date:  2021-01-05       Impact factor: 1.214

7.  Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.

Authors:  Jung Lung Hsu; Ming-Feng Liao; Kuo-Hsuan Chang; Mei-Yun Cheng; Long-Sun Ro
Journal:  BMC Neurol       Date:  2021-04-09       Impact factor: 2.474

8.  The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients.

Authors:  Ahmad Al-Serri; Raed Alroughani; Rabeah A Al-Temaimi
Journal:  Sci Rep       Date:  2019-12-13       Impact factor: 4.379

9.  Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2020-09-29       Impact factor: 4.981

Review 10.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.